The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis.

Human gene therapy. Clinical development

Volumn 24, Issue 2, 2013, Pages 47-54

  Aiuti, Alessandro ^a   Cossu, Giulio ^b   de Felipe, Pablo ^b   Galli, Maria Cristina ^b   Narayanan, Gopalan ^b   Renner, Matthias ^b   Stahlbom, Axel ^b   Schneider, Christian K ^b   Voltz Girolt, Caroline ^b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); EUROPEAN UNION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LEUKEMIA; METABOLISM; MOUSE; RISK FACTOR; TISSUE ENGINEERING; TRANSGENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; EUROPEAN UNION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LEUKEMIA; MICE; MUTAGENESIS, INSERTIONAL; RISK FACTORS; TISSUE ENGINEERING; TISSUE THERAPY; TRANSGENES;

EID: 84886648166     PISSN: None     EISSN: 23248645     Source Type: None    
DOI: 10.1089/humc.2013.119     Document Type: Article

References (0)